Cancer treatment developer GammaCan raised $6.5 million March 6, 2007
Posted by israelhealthcare in Drug Discovery.Tags: cancer, immunotherapy, melanoma
add a comment
GammaCan, a developer of novel immunotherapies to treat cancer, raised $6.5 million in a private placement with a group of investors lead by T.R. Winston & Company.
“These funds will enable us to continue the development of VitiGam for the treatment of Stage III and Stage IV melanoma,” said Patrick Schnegelsberg, CEO.
GammaCan develops innovative immunotherapy and related approaches to treat cancer. GammaCan is planning to submit its Investigational New Drug Application (IND) for VitiGam to the FDA in the near future. The Company is expecting to commence human clinical trials shortly thereafter.
VitiGam is a first-in-class IgG-based anti-cancer immunotherapy being developed for the treatment of Stage III and Stage IV melanoma. VitiGam is an IgG-based product manufactured from the plasma of donors with Vitiligo, a benign skin condition affecting up to 2% of the general population.
Sponsored Links – Garlic Grinder | Sequential Compression Device | Derma Skin Care Ointments
Israel Healthcare & Medical Device Industry 